Literature DB >> 1688689

Lack of effect of colony-stimulating factors, interleukins, interferons, and tumor necrosis factor on the growth and differentiation of cultured Reed-Sternberg cells. Comparison with effects of phorbol ester and retinoic acid.

S M Hsu1, P L Hsu.   

Abstract

The neoplastic Hodgkin's Reed-Sternberg (H-RS) cells in Hodgkin's disease are surrounded in vivo by abundant reactive cells, the function of which may be attributed in part to their elaboration of various cytokines. Thus, a study of the interaction of H-RS cells with exogenous cytokines may provide information as to the mechanism of the clinical and histopathologic changes observed in Hodgkin's disease. This study examined the effect of various cytokines, and of phorbol ester (TPA) and retinoic acid, on the differentiation and proliferation of cultured H-RS cells (cell lines HDLM-1 and KM-H2). In addition, it was determined whether these cells were able to secrete cytokines after being treated with exogenous cytokines. The cytokines used included various types of interleukins (1, 2, and 3), colony-stimulating factors (GM, G, and M), interferons (alpha, beta, and gamma), and tumor necrosis factor (alpha). It was found that these cytokines, used alone or in combination, were not effective in modulating the proliferation and differentiation of cells, or the production of cytokines, in cultured H-RS cells. In contrast, this study revealed that retinoic acid can potentiate TPA-induced growth inhibition in cultured H-RS cells. Retinoic acid, when used alone, exhibited a minimal effect on cell differentiation. No synergistic effects of cytokines and retinoic acid on H-RS cells were observed. The failure of cultured H-RS cells to respond to exogenous cytokines suggests that, during the course of neoplastic transformation, of progression of disease, or of establishment of the cells in culture, H-RS cells lose their dependence on cytokines, although they retain the capacity to produce various cytokines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688689      PMCID: PMC1877445     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  Monoclonal antibodies against SU-DHL-1 cells stain the neoplastic cells in true histiocytic lymphoma, malignant histiocytosis, and Hodgkin's disease.

Authors:  S M Hsu; M D Pescovitz; P L Hsu
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

2.  Heterogeneity of interleukin 1 production in cultured Reed-Sternberg cell lines HDLM-1, HDLM-1d, and KM-H2.

Authors:  S M Hsu; K Krupen; L B Lachman
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

3.  Extracellular matrix does not induce the proliferation, but promotes the differentiation, of Hodgkin's cell line HDLM-1.

Authors:  S M Hsu; X Zhao; P L Hsu; M S Lok
Journal:  Am J Pathol       Date:  1987-04       Impact factor: 4.307

4.  Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells.

Authors:  U Schwab; H Stein; J Gerdes; H Lemke; H Kirchner; M Schaadt; V Diehl
Journal:  Nature       Date:  1982-09-02       Impact factor: 49.962

Review 5.  Retinoids as preventive and therapeutic anticancer agents (Part I).

Authors:  S M Lippman; J F Kessler; F L Meyskens
Journal:  Cancer Treat Rep       Date:  1987-04

6.  Priming of human myeloid leukemic cell lines HL-60 and U-937 with retinoic acid for differentiation effects of cyclic adenosine 3':5'-monophosphate-inducing agents and a T-lymphocyte-derived differentiation factor.

Authors:  I L Olsson; T R Breitman; R C Gallo
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

7.  Induction of differentiation of the human histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3':5'-monophosphate-inducing agents.

Authors:  I L Olsson; T R Breitman
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

8.  Production of colony-stimulating factors by Hodgkin cell lines.

Authors:  H Burrichter; W Heit; M Schaadt; H Kirchner; V Diehl
Journal:  Int J Cancer       Date:  1983-03-15       Impact factor: 7.396

9.  Gamma-interferon induces expression of the HLA-D antigens on normal and leukemic human myeloid cells.

Authors:  H P Koeffler; J Ranyard; L Yelton; R Billing; R Bohman
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

10.  Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles.

Authors:  H G Drexler; G Gaedicke; M S Lok; V Diehl; J Minowada
Journal:  Leuk Res       Date:  1986       Impact factor: 3.156

View more
  4 in total

1.  Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease.

Authors:  S M Hsu; S S Xie; P L Hsu; J A Waldron
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

2.  Cultured Reed-Sternberg cells HDLM-1 and KM-H2 can be induced to become histiocytelike cells. H-RS cells are not derived from lymphocytes.

Authors:  S M Hsu; S S Xie; P L Hsu
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

3.  Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study.

Authors:  L P Ruco; D Pomponi; R Pigott; A Stoppacciaro; F Monardo; S Uccini; D Boraschi; A Tagliabue; A Santoni; E Dejana
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

4.  Expression and cell distribution of the intercellular adhesion molecule, vascular cell adhesion molecule, endothelial leukocyte adhesion molecule, and endothelial cell adhesion molecule (CD31) in reactive human lymph nodes and in Hodgkin's disease.

Authors:  L P Ruco; D Pomponi; R Pigott; A J Gearing; A Baiocchini; C D Baroni
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.